NUWE Stock Forecast: Nuwellis, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 18 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Nuwellis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (53): Reported profit is backed by cash, and the company is not expanding recklessly.
Value (0): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
NUWE stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NUWE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Aug 2024 | Roth MKM | Reiterates | Buy | $17 |
| 29 July 2024 | Roth MKM | Initiates | Buy | — |
| 8 Nov 2023 | Ladenburg Thalmann | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NUWE.
This page is one stock. Monday covers all of them.
NUWE appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
NUWE vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Nuwellis, Inc. returned −95.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
NUWE analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.0×
- Price / sales
- 0.2×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 99% of US stocks
Cheaper than 90% of US stocks
- Revenue growth (YoY)
- 14.1%
- Earnings growth (YoY)
- —
- Gross margin
- 76.1%
- Operating margin
- —
- Net margin
- —
Higher than 62% of US stocks
Higher than 88% of US stocks
- Return on equity
- —
- Return on assets
- −87.8%
- Dividend yield
- —
Higher than 4% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Nuwellis, Inc. has a market value of $2.1M.
Revenue in the twelve months to 30 June 2026: $9.0M. The latest quarter grew 14.1% year on year.
Net income over the same four quarters: −$11.3M, a −125.6% net margin.
Diluted earnings per share, trailing twelve months: −$132.69.
Free cash flow in the twelve months to 30 June 2026: −$12.7M.
Trailing P/E: 0.0×.
Nuwellis, Inc. employs 38 people — $237K of revenue per employee.
Data provided by Twelve Data
NUWE and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at NUWE’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Nuwellis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about NUWE
Is NUWE stock a buy right now?
Of the 1 analyst covering Nuwellis, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nuwellis, Inc. 18 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank NUWE?
As at 21 Nov 2026, Nuwellis, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (53 of 100).
What is the NUWE stock forecast for 2030?
No analyst covering Nuwellis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NUWE are extrapolating price history, which says nothing about the business.
How has NUWE stock performed over the past year?
Nuwellis, Inc. returned -95.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Nuwellis, Inc. do?
Nuwellis, Inc. is a medical technology company focused on fluid management for patients with cardiorenal and cardiovascular conditions. The company develops and commercializes ultrafiltration therapy systems, including the Aquadex SmartFlow and Aquadex FlexFlow platforms, which are designed to remove excess fluid when conventional medical management, such as diuretics, is not sufficient.
About Nuwellis, Inc.
Nuwellis, Inc. is a medical technology company focused on fluid management for patients with cardiorenal and cardiovascular conditions. The company develops and commercializes ultrafiltration therapy systems, including the Aquadex SmartFlow and Aquadex FlexFlow platforms, which are designed to remove excess fluid when conventional medical management, such as diuretics, is not sufficient. Its devices are used in hospital settings for adult and pediatric patients, supporting clinicians in acute and critical care environments. Nuwellis serves the healthcare market through products intended to address fluid overload, a condition associated with heart failure and related complications. Headquartered in Eden Prairie, Minnesota, Nuwellis concentrates on specialized medical devices that help providers manage complex fluid-balance needs across a range of clinical settings.
CEO Mr. Michael Kendrick McCormick · 38 employees · United States · https://www.nuwellis.com